Novartis was a pioneer in gene therapy with the successful development of Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy. And while some big pharmas have backed away from the space, the Swiss pharma is continuing to invest. The company announced the acquisition of the privately held gene therapy developer Kate Therapeutics on 21 November, agreeing to pay up to $1.1bn, including an upfront payment and milestone payments.
Novartis Gains Next-Generation Gene Therapy Tech With Kate Acquisition
The Swiss pharma acquired Kate Therapeutics for up to $1.1bn, gaining preclinical gene therapies for neuromuscular conditions and novel platform technology.
